{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:51:10Z","timestamp":1773741070537,"version":"3.50.1"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100009600","name":"Beijing University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["040204001001002026"],"award-info":[{"award-number":["040204001001002026"]}],"id":[{"id":"10.13039\/501100009600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2020,3,16]]},"abstract":"<jats:sec>\n<jats:title>Aim and Objective:<\/jats:title>\n<jats:p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a\ncommon chronic kidney disease that leads to End-Stage Renal Disease (ESRD). The key target of\nthis therapy is to prevent the progression of kidney failure. Tolvaptan could slow kidney cyst\ngrowth and are proven highly effective. The aims of this analysis are to perform a systematic\nreview, estimate and evaluate the efficacy and safety of tolvaptan in ADPKD patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>Randomized controlled trials of tolvaptan in ADPKD were identified in\nPubMed, Ovid, Web of Science and the Cochrane Library electronic database. The changes\nobserved in kidney function, treatment efficiency and the incidence of adverse events between the\ntolvaptan and placebo groups were compared. Data were analyzed by the RevMan software.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Eight trials, including 7 double-blinded randomised controlled trials and 1 quasi RCT\ninvolving 1,536 patients were extracted. Significant differences in the annual rate of change in the\ntotal kidney volume TKV at any stages of CKD (MD = -3.32, 95%CI =-4.57,-2.07, I2 =70%) and\nthe glomerular filtration rate (MD = 1.4, 95%CI = 0.83,1.97, I2 =0%) were observed between the\ntolvaptan group and the placebo group. Subgroup analysis of patients in different CKD stages also\nshowed the same conclusion. There was an increase in the urine osmolality, and 24-hour urine\nvolume in patients receiving tolvaptan. Tolvaptan reduced the rate of serious hypertension and\nkidney pain events in ADPKD patients. At higher doses, it increased the rate of adverse events\n(liver injuries, thirst, pollakiuria, and nocturia). There was no significant risk of bias in the\nincluded studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>Tolvaptan has a beneficial effect on ADPKD, but is associated with an increase in\nadverse events at high doses when compared with the placebo. Further RCTs on tolvaptan may be\nrequired to support this conclusion.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207322666191203092715","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T13:38:22Z","timestamp":1575380302000},"page":"6-16","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis"],"prefix":"10.2174","volume":"23","author":[{"given":"Xuan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Nephropathy, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hai","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Beijing Fangshan District City Hospital of Traditional Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Zhong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Kui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, First People\u2019s Hospital of Dongcheng District, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Acupuncture and Moxibustion, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"Torres V.E.","year":"2009","unstructured":"Torres V.E.; Harris P.C.; Pirson Y.; Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009,76(2),149-168","journal-title":"Kidney Int"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"Torres V.E.","year":"2007","unstructured":"Torres V.E.; Harris P.C.; Pirson Y.; Autosomal dominant polycystic kidney disease. Lancet 2007,369(9569),1287-1301","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3238\/arztebl.2015.0884","volume":"112","author":"K\u00fchn W.E.","year":"2015","unstructured":"K\u00fchn W.E.; Walz G.; The treatment of autosomal dominant polycystic kidney disease. Dtsch Arztebl Int 2015,112(51-52),884-890","journal-title":"Dtsch Arztebl Int"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-015-0475-x","volume":"75","author":"Blair H.A.","year":"2015","unstructured":"Blair H.A.; Keating G.M.; Tolvaptan: a review in autosomal dominant polycystic kidney disease. Drugs 2015,75(15),1797-1806","journal-title":"Drugs"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.pap.0000201831.77472.d3","volume":"13","author":"Bisceglia M.","year":"2006","unstructured":"Bisceglia M.; Galliani C.A.; Senger C.; Stallone C.; Sessa A.; Renal cystic diseases: a review. Adv Anat Pathol 2006,13(1),26-56","journal-title":"Adv Anat Pathol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"Grantham J.J.","year":"2008","unstructured":"Grantham J.J.; Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008,359(14),1477-1485","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5301\/GTND.2016.15862","volume":"28","author":"Santoro D.","year":"2016","unstructured":"Santoro D.; New options for the management of polycystic kidney disease. J. Nephrological Dialysis Techniques 2016,28(2),143-152","journal-title":"Nephrological Dialysis Techniques"},{"key":"ref=8","first-page":"25","volume":"22","author":"Edelstein C.L.","year":"2008","unstructured":"Edelstein C.L.; Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues 2008,22(3),25-26","journal-title":"Nephrol News Issues"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"Torres V.E.","year":"2016","unstructured":"Torres V.E.; Higashihara E.; Devuyst O.; Chapman A.B.; Gansevoort R.T.; Grantham J.J.; Perrone R.D.; Ouyang J.; Blais J.D.; Czerwiec F.C.; Effect of tolvaptan in autosomal dominant polycystic kidney disease by ckd stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 2016,11(5),803-811","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13730-016-0230-5","volume":"5","author":"Uchiyama K.","year":"2016","unstructured":"Uchiyama K.; Honda K.; Yoshida R.; Kamijo Y.; Yanagi M.; Nakatsuka M.; Ishibashi Y.; Effect of tolvaptan in a patient with autosomal dominant polycystic kidney disease after living donor liver transplantation. CEN Case Rep 2016,5(2),227-231","journal-title":"CEN Case Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/phar.1421","volume":"34","author":"Baur B.P.","year":"2014","unstructured":"Baur B.P.; Meaney C.J.; Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy 2014,34(6),605-616","journal-title":"Pharmacotherapy"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","volume":"31","author":"Gansevoort R.T.","year":"2016","unstructured":"Gansevoort R.T.; Meijer E.; Chapman A.B.; Czerwiec F.S.; Devuyst O.; Grantham J.J.; Higashihara E.; Krasa H.B.; Ouyang J.; Perrone R.D.; Torres V.E.; TEMPO 3:4 Investigators. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant 2016,31(11),1887-1894","journal-title":"Nephrol Dial Transplant"},{"key":"ref=13","author":"Torres V.E.","year":"2014","unstructured":"Torres V.E.;  Tolvaptan-treatment of ADPKD confers persistent EGFR improvement: results from the TEMPO 4:4 extension trial.  2014"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-311535.61","volume":"101","author":"Olalekan K.","year":"2016","unstructured":"Olalekan K.; Fox A.; Gilbert R.; TOLVAPTAN use in severe neonatal autosomal dominant polycystic kidney disease (ADPKD): the pharmaceutical challenge. Arch Dis Child 2016,101(9)","journal-title":"Arch Dis Child"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","volume":"69","author":"Casteleijn N.F.","year":"2017","unstructured":"Casteleijn N.F.; Blais J.D.; Chapman A.B.; Czerwiec F.S.; Devuyst O.; Higashihara E.; Leliveld A.M.; Ouyang J.; Perrone R.D.; Torres V.E.; Gansevoort R.T.; TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3:4 trial investigators. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis 2017,69(2),210-219","journal-title":"Am J Kidney Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"Devuyst O.","year":"2016","unstructured":"Devuyst O.; Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol 2016,28(5),1592-1602","journal-title":"J Am Soc Nephrol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"Torres V.E.","year":"2012","unstructured":"Torres V.E.; Chapman A.B.; Devuyst O.; Gansevoort R.T.; Grantham J.J.; Higashihara E.; Perrone R.D.; Krasa H.B.; Ouyang J.; Czerwiec F.S.; TEMPO 3:4 trial investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012,367(25),2407-2418","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"Higashihara E.","year":"2011","unstructured":"Higashihara E.; Torres V.E.; Chapman A.B.; Grantham J.J.; Bae K.; Watnick T.J.; Horie S.; Nutahara K.; Ouyang J.; Krasa H.B.; Czerwiec F.S.; TEMPO formula and 156-05-002 study investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience. Clin J Am Soc Nephrol 2011,6(10),2499-2507","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12882-017-0686-3","volume":"18","author":"Al Therwani S.","year":"2017","unstructured":"Al Therwani S.; Malmberg M.E.S.; Rosenbaek J.B.; Bech J.N.; Pedersen E.B.; Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. BMC Nephrol 2017,18(1),268","journal-title":"BMC Nephrol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"Watkins P.B.","year":"2015","unstructured":"Watkins P.B.; Lewis J.H.; Kaplowitz N.; Alpers D.H.; Blais J.D.; Smotzer D.M.; Krasa H.; Ouyang J.; Torres V.E.; Czerwiec F.S.; Zimmer C.A.; Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 2015,38(11),1103-1113","journal-title":"Drug Saf"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"Torres V.E.","year":"2016","unstructured":"Torres V.E.; Higashihara E.; Devuyst O.; Chapman A.B.; Gansevoort R.T.; Grantham J.J.; Perrone R.D.; Ouyang J.; Blais J.D.; Czerwiec F.S.; TEMPO 3:4 trial investigators. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 2016,11(5),803-811","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=22","volume":"33","author":"Cirillo M.","year":"2016","unstructured":"Cirillo M.; Treatment of autosomal dominant polycystic kidney\ndisease (ADPKD) - Tolvaptan. G Ital Entomol, pii:\ngin\/33.5.21.2016,33(5)","journal-title":"G Ital Entomol,"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.urology.2012.12.002","volume":"81","author":"Black P.","year":"2013","unstructured":"Black P.; Sutton R.; Commentary on: Tolvaptan in patients with autosomal-dominant polycystic kidney disease. Urology 2013,81(4),705-706","journal-title":"Urology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13730-015-0198-6","volume":"5","author":"Kai H.","year":"2016","unstructured":"Kai H.; Shinozaki Y.; Nishikubo A.; Watanabe M.; Tawara T.; Iwase M.; Tsunoda R.; Moriyama N.; Usui T.; Kawamura T.; Nagai K.; Hagiwara M.; Saito C.; Morito N.; Usui J.; Yamagata K.; Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan. CEN Case Rep 2016,5(1),87-90","journal-title":"CEN Case Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"Torres V.E.","year":"2011","unstructured":"Torres V.E.; Meijer E.; Bae K.T.; Chapman A.B.; Devuyst O.; Gansevoort R.T.; Grantham J.J.; Higashihara E.; Perrone R.D.; Krasa H.B.; Ouyang J.J.; Czerwiec F.S.; Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis 2011,57(5),692-699","journal-title":"Am J Kidney Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1093\/ndt\/gfp136","volume":"24","author":"Azurmendi P.J.","year":"2009","unstructured":"Azurmendi P.J.; Fraga A.R.; Galan F.M.; Kotliar C.; Arrizurieta E.E.; Valdez M.G.; Forcada P.J.; Stefan J.S.; Martin R.S.; Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function. Nephrol Dial Transplant 2009,24(8),2458-2463","journal-title":"Nephrol Dial Transplant"},{"key":"ref=27","year":"2014","unstructured":"A study to investigate the long-term safety and efficacy of\ntolvaptan in patients with autosomal dominant polycystic kidney\ndisease (ADPKD). [Extension of Trial 156-04-251 in Japan] (ClinicalTrials.gov Identifier: NCT01280721).2014"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10157-016-1297-1","volume":"21","author":"Casteleijn N.F.","year":"2017","unstructured":"Casteleijn N.F.; Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clin Exp Nephrol 2017,21(3),375-382","journal-title":"Clin Exp Nephrol"},{"key":"ref=29","first-page":"969","volume":"32","author":"Grantham J.J.","year":"2017","unstructured":"Grantham J.J.; Chapman A.B.; Blais J.; Czerwiec F.S.; Devuyst O.; Gansevoort R.T.; Higashihara E.; Krasa H.; Zhou W.; Ouyang J.; Perrone R.D.; Torres V.E.; TEMPO 3:4 Investigators. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 2017,32(6),969-975","journal-title":"Nephrol Dial Transplant"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s40278-013-1101-x","volume":"1437","year":"2013","unstructured":"Risk of liver injury with Tolvaptan. Reactions Weekly  2nd February2013,1437(1),2-2","journal-title":"Reactions Weekly"},{"key":"ref=31","first-page":"367","volume":"69","author":"van Gulick J.J.","year":"2011","unstructured":"van Gulick J.J.; Gevers T.J.; van Keimpema L.; Drenth J.P.; Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum. Neth J Med 2011,69(9),367-371","journal-title":"Neth J Med"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/177112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T03:42:29Z","timestamp":1586403749000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/177112\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207322666191203092715","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}